Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 open-label study of amonafide L-malate in combination with cytarabine in subjects with secondary acute myeloid leukemia (AML)

Next Previous
X
Search
Trial Profile

Phase 2 open-label study of amonafide L-malate in combination with cytarabine in subjects with secondary acute myeloid leukemia (AML)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amonafide (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Antisoma

    • Most Recent Events

    • 05 Jun 2010 Results presented at the ASCO 2010, according to a Antisoma media release.
    • 07 Dec 2009 Final results presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH 2009), according to a Antisoma media release.
    • 09 Dec 2008 Updated results were presented at the 50th Annual Meeting of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top